Budesonide (Entocort EC) vs budesonide (Ortikos)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: Glucocorticoid receptor · full Crohn's Disease pipeline
Budesonide (Entocort EC)
Marketed by Padagis and partners
NCT01444092 · Phase 3 · completed
This was a single-arm, open-label study without randomization, blinding, or a comparator, so its findings cannot reliably distinguish Entocort’s effects from the natural course of disease or other factors. The primary safety endpoint was descriptive rather than a comparative efficacy test, with 79 of 108 treated participants reporting at least one adverse event.
Reported efficacy
Adverse Event (12 weeks): Single-arm safety study; primary outcome adverse events at 12 weeks: 79 of 108 treated children (73%) had at least one adverse event. Secondary: PCDAI fell from a mean of 19.1 at baseline by 10.0 (SD 10.1, n=105) at 8 weeks; IMPACT III rose by 7.8 (SD 13.3). (not_applicable)
Result source: NCT01444092
budesonide (Ortikos)
Rights held by Sun Pharmaceutical Industries; US product discontinued
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Budesonide (Entocort EC) | budesonide (Ortikos) |
|---|---|---|
| Clinical remission (induction) | —Not reported | —Not reported |
| Endoscopic response (induction) | —Not reported | —Not reported |
| Clinical remission (maintenance) | —Not reported | —Not reported |
| Endoscopic response (maintenance) | —Not reported | —Not reported |
Clinical remission (induction)
- Budesonide (Entocort EC)
- —Not reported
- budesonide (Ortikos)
- —Not reported
Endoscopic response (induction)
- Budesonide (Entocort EC)
- —Not reported
- budesonide (Ortikos)
- —Not reported
Clinical remission (maintenance)
- Budesonide (Entocort EC)
- —Not reported
- budesonide (Ortikos)
- —Not reported
Endoscopic response (maintenance)
- Budesonide (Entocort EC)
- —Not reported
- budesonide (Ortikos)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Budesonide (Entocort EC): registry results are on file for Crohn's Disease, but their comparison mappings are not yet available.
budesonide (Ortikos): no structured comparison results are available for Crohn's Disease.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Budesonide (Entocort EC)'s landscape · budesonide (Ortikos)'s landscape